Long-term therapeutic potential of resveratrol on the progression of muscle atrophy in a mouse model of congenital muscular dystrophy

2015 Fiscal Year Final Research Report

• Project/Area Number: 25350634
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Rehabilitation science/Welfare engineering
• Research Institution: Teikyo University of Science & Technology
• Principal Investigator: HAGIWARA HIROKI 帝京科学大学, 公私立大学の部局等, 教授 (80276732)
• Co-Investigator(Kenkyū-buntansha): Masaki Toshihiro 帝京科学大学, 医療科学部, 教授 (00585028) ; SAITO Fumiaki 帝京大学, 医学部, 准教授 (40286993) ; HIROSE Noboru 帝京科学大学, 医療科学部, 准教授 (60460391)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: レスベラトロール / サーチュイン 1 / 先天性筋ジストロフィー / 筋原性制御因子 / 線維化 / オステオポンチン / 廃用性筋萎縮

Outline of Final Research Achievements

Resveratrol (RSV), a naturally derived polyphenol, has recently shown to exhibit anti-aging effects by activating SIRT1 (sirtuin 1). To examine the long-term therapeutic potential of on muscular dystrophies, we examined whether pathogenesis in dy-2J mice (a model for congenital muscular dystrophy type 1A (MDC1A)) is ameliorated by prolonged administration of resveratrol. RSV was orally administered ad libitum to mice for over 1 year. We compared resveratrol administrated (RSV-treated) with control (non-treated) groups by physiological and histological analyses. RSV-treated group showed a significant improve in body weight, muscle strength and locomotive activities than control group. By histological analysis, we found that RSV-treated group showed larger in cell size and less fibrosis in comparison with control group. These results suggest that long-term administration of resveratrol suppresses the progression of muscular dystrophy in dy-2J model mice by reducing fibrosis.

Free Research Field

筋生物学